|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income (loss) | |||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||
| Depreciation and amortization | |||||
| Loss on disposal of property, plant and equipment | |||||
| Stock-based compensation | |||||
| Deferred income taxes | |||||
| Interest on end-of-term debt obligation | |||||
| Non-cash lease expense | |||||
| Revaluation of acquisition-related contingent consideration | |||||
| Amortization of discount on short-term investments | |||||
| Impairment loss | |||||
| Non-cash loss on deconsolidation of subsidiary | |||||
| Effect of foreign currency on operations | |||||
| Changes in operating assets and liabilities: | |||||
| Accounts receivable | |||||
| Supplies and inventory | |||||
| Prepaid expenses and other current assets | |||||
| Other assets | |||||
| Operating lease liability | |||||
| Accounts payable | |||||
| Accrued liabilities and deferred revenue | |||||
| Net cash provided by operating activities | |||||
| Investing activities | |||||
| Purchase of short-term investments | |||||
| Proceeds from sale of short-term investments | |||||
| Proceeds from maturity of short-term investments | |||||
| Loss on deconsolidation of subsidiary - cash | |||||
| Acquisition of C2i, net of cash acquired | |||||
| Acquisition of HalioDx, net of cash acquired | |||||
| Proceeds from sale of equity securities | |||||
| Purchases of property, plant and equipment | |||||
| Net cash (used in) provided by investing activities | |||||
| Financing activities | |||||
| Proceeds from issuance of common stock in a public offering, net of issuance costs | |||||
| Payment of contingent consideration for acquisition | |||||
| Payment of long-term debt | |||||
| Payment of taxes on vested restricted stock units | |||||
| Proceeds from the exercise of common stock options and employee stock purchases | |||||
| Net cash (used in) provided by financing activities | |||||
| Increase in cash, cash equivalents and restricted cash | |||||
| Effect of foreign currency on cash, cash equivalents and restricted cash | |||||
| Net increase in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash at beginning of year | |||||
| Cash, cash equivalents and restricted cash at end of year | |||||
| Supplementary cash flow information of non-cash investing and financing activities: | |||||
| Shares issued for purchase consideration for a business combination | |||||
| Purchases of property and equipment included in accounts payable and accrued liabilities | |||||
| Cash paid for interest on debt | |||||
| Cash paid for tax | |||||
| Cash and cash equivalents | |||||
| Restricted cash | |||||
Loading...